As of 2026-03-02, the EV/EBITDA ratio of Fulgent Genetics Inc (FLGT) is -12.95. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FLGT's latest enterprise value is 604.57 mil USD. FLGT's TTM EBITDA according to its financial statements is -46.67 mil USD. Dividing these 2 quantities gives us the above FLGT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.5x - 13.9x | 12.1x |
| Forward P/E multiples | 9.0x - 11.4x | 10.2x |
| Fair Price | (7.02) - (8.91) | (8.65) |
| Upside | -145.8% - -158.1% | -156.4% |
| Date | EV/EBITDA |
| 2026-02-27 | -12.95 |
| 2026-02-26 | -22.43 |
| 2026-02-25 | -21.23 |
| 2026-02-24 | -20.75 |
| 2026-02-23 | -20.67 |
| 2026-02-20 | -20.84 |
| 2026-02-19 | -20.94 |
| 2026-02-18 | -21.01 |
| 2026-02-17 | -21.27 |
| 2026-02-13 | -21.10 |
| 2026-02-12 | -20.63 |
| 2026-02-11 | -20.66 |
| 2026-02-10 | -20.72 |
| 2026-02-09 | -20.61 |
| 2026-02-06 | -21.11 |
| 2026-02-05 | -21.38 |
| 2026-02-04 | -23.21 |
| 2026-02-03 | -23.74 |
| 2026-02-02 | -23.80 |
| 2026-01-30 | -23.88 |
| 2026-01-29 | -23.92 |
| 2026-01-28 | -24.08 |
| 2026-01-27 | -24.96 |
| 2026-01-26 | -25.22 |
| 2026-01-23 | -25.51 |
| 2026-01-22 | -25.86 |
| 2026-01-21 | -25.54 |
| 2026-01-20 | -25.38 |
| 2026-01-16 | -25.77 |
| 2026-01-15 | -26.34 |
| 2026-01-14 | -25.66 |
| 2026-01-13 | -26.05 |
| 2026-01-12 | -25.85 |
| 2026-01-09 | -25.54 |
| 2026-01-08 | -25.58 |
| 2026-01-07 | -25.70 |
| 2026-01-06 | -23.67 |
| 2026-01-05 | -23.05 |
| 2026-01-02 | -23.27 |
| 2025-12-31 | -23.95 |
| 2025-12-30 | -24.17 |
| 2025-12-29 | -24.28 |
| 2025-12-26 | -24.40 |
| 2025-12-24 | -24.70 |
| 2025-12-23 | -24.85 |
| 2025-12-22 | -25.33 |
| 2025-12-19 | -25.30 |
| 2025-12-18 | -25.75 |
| 2025-12-17 | -25.19 |
| 2025-12-16 | -24.85 |